This marks the sixth FDA clearance the NY-based company has received.

Study findings point out the device met the primary safety endpoint compared to historical controls but did not demonstrate superiority for the primary hierarchical efficacy endpoint.

These are the companies in the private sector that medtech analysts have called attention to in 2021.

Results from the SCOPE II trial were presented at TCT Connect and showed the Acurate Neo failed to demonstrate non-inferiority when compared to Medtronic’s CoreValve Evolut.

The Chicago, IL-based company has received FDA clearance for the Vivid Ultra Edition, an AI-powered cardiovascular ultrasound system.

Boston Scientific has a plan to tackle systemic racism in healthcare, and to stop the "Black amputation epidemic."

The Marlborough, MA-based company received CE mark for the valve in April. Boston Scientific gained access to Acurate when it closed its $435 million acquisition of Symetis.

The Dublin-based company said TYRX is intended to securely hold a percutaneous driveline in patients.

The Marlborough, MA-based company made a significant investment into Farapulse, the developer of the pulsed-field ablation (PFA) system.